Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Gain Therapeutics Inc.

    NASDAQ: GANX · Real-Time Price · USD
    1.69
    -0.05 (-2.87%)
    At close: Jun 17, 2025, 3:26 PM

    Gain Therapeutics Statistics

    Share Statistics

    Gain Therapeutics has 29.95M shares outstanding. The number of shares has increased by 46.94% in one year.

    Shares Outstanding

    n/a
    		 29.95M

    Shares Change (YoY)

    n/a
    		 46.94%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 7.48%

    Shares Floating

    n/a
    		 28.48M

    Failed to Deliver (FTD) Shares

    n/a
    		 1,278

    FTD / Avg. Volume

    n/a
    		 0.47%

    Short Selling Information

    The latest short interest is 291.84K, so 0.99% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 291.84K

    Short % of Shares Out

    n/a
    		 0.99%

    Short % of Float

    n/a
    		 1.03%

    Short Ratio (days to cover)

    n/a
    		 1.54

    Valuation Ratios

    The PE ratio is -2.42 and the forward PE ratio is -2.45. Gain Therapeutics's PEG ratio is 0.05.

    PE Ratio

    n/a
    		 -2.42

    Forward PE

    n/a
    		 -2.45

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 2.4

    PB Ratio

    n/a
    		 6.73

    P/FCF Ratio

    n/a
    		 -2.62

    PEG Ratio

    n/a
    		 0.05
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Gain Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 2.97, with a Debt / Equity ratio of 0.09.

    Current Ratio

    n/a
    		 2.97

    Quick Ratio

    n/a
    		 2.97

    Debt / Equity

    n/a
    		 0.09

    Debt / EBITDA

    n/a
    		 -0.03

    Debt / FCF

    n/a
    		 -0.03

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-887,443.09

    Employee Count

    n/a
    		 23

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 536.82K

    Effective Tax Rate

    n/a
    		 -2.7%

    Stock Price Statistics

    The stock price has increased by 31.06% in the last 52 weeks. The beta is 0.11, so Gain Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.11

    52-Week Price Change

    n/a
    		 31.06%

    50-Day Moving Average

    n/a
    		 1.85

    200-Day Moving Average

    n/a
    		 1.96

    Relative Strength Index (RSI)

    n/a
    		 41.1

    Average Volume (20 Days)

    n/a
    		 274,365

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -20.35M

    Net Income

    n/a
    		 -20.41M

    EBITDA

    n/a
    		 -19.79M

    EBIT

    n/a
    		 -19.87M

    Earnings Per Share (EPS)

    n/a
    		 -0.89
    Full Income Statement

    Balance Sheet

    The company has 10.39M in cash and 653.01K in debt, giving a net cash position of 9.73M.

    Cash & Cash Equivalents

    n/a
    		 10.39M

    Total Debt

    n/a
    		 653.01K

    Net Cash

    n/a
    		 9.73M

    Retained Earnings

    n/a
    		 -81.19M

    Total Assets

    n/a
    		 11.62M

    Working Capital

    n/a
    		 6.12M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -18.87M and capital expenditures -22.49K, giving a free cash flow of -18.9M.

    Operating Cash Flow

    n/a
    		 -18.87M

    Capital Expenditures

    n/a
    		 -22.49K

    Free Cash Flow

    n/a
    		 -18.9M

    FCF Per Share

    n/a
    		 -0.83
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    GANX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for GANX is $7.5, which is 333.5% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $7.5

    Price Target Difference

    n/a
    		 333.5%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 5
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -9.46

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist